高级检索
当前位置: 首页 > 详情页

USP47 deficiency in mice modulates tumor infiltrating immune cells and enhances antitumor immune responses in prostate cancer

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Shanghai Jiao Tong Univ, Sch Med, Shanghai Ruijin Hosp, State Key Lab Med Genom,Res Ctr Expt Med, Shanghai 200025, Peoples R China [2]Shanghai Model Organisms Ctr, Shanghai 201321, Peoples R China [3]Shanghai Jiao Tong Univ, Key Lab Cell Differentiat & Apoptosis, Shanghai Tongren Hosp,Fac Basic Med,Dept Pathophys, Hongqiao Int Inst Med,Chinese Minist Educ,Sch Med, Shanghai 200025, Peoples R China [4]Shanghai Jiao Tong Univ, Sch Med, Shanghai Inst Immunol, Shanghai 200025, Peoples R China
出处:
ISSN:

关键词: USP47 Tumor microenvironment TIL CTL

摘要:
This study investigates the role of USP47, a deubiquitinating enzyme, in the tumor microenvironment and its impact on antitumor immune responses. Analysis of TCGA database revealed distinct expression patterns of USP47 in various tumor tissues and normal tissues. Prostate adenocarcinoma showed significant downregulation of USP47 compared to normal tissue. Correlation analysis demonstrated a positive association between USP47 expression levels and infiltrating CD8+ T cells, neutrophils, and macrophages, while showing a negative correlation with NKT cells. Furthermore, using Usp47 knockout mice, we observed a slower tumor growth rate and reduced tumor burden. The absence of USP47 led to increased infiltration of immune cells, including neutrophils, macrophages, NK cells, NKT cells, and T cells. Additionally, USP47 deficiency resulted in enhanced activation of cytotoxic T lymphocytes (CTLs) and altered T cell subsets within the tumor microenvironment. These findings suggest that USP47 plays a critical role in modulating the tumor microenvironment and promoting antitumor immune responses, highlighting its potential as a therapeutic target in prostate cancer.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2023]版:
大类 | 2 区 医学
小类 | 3 区 免疫学 3 区 肿瘤学
最新[2025]版:
大类 | 3 区 医学
小类 | 3 区 免疫学 3 区 肿瘤学
JCR分区:
出版当年[2022]版:
Q1 ONCOLOGY Q2 IMMUNOLOGY
最新[2024]版:
Q1 IMMUNOLOGY Q1 ONCOLOGY

影响因子: 最新[2024版] 最新五年平均 出版当年[2022版] 出版当年五年平均 出版前一年[2021版] 出版后一年[2023版]

第一作者:
第一作者机构: [1]Shanghai Jiao Tong Univ, Sch Med, Shanghai Ruijin Hosp, State Key Lab Med Genom,Res Ctr Expt Med, Shanghai 200025, Peoples R China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:28494 今日访问量:0 总访问量:1584 更新日期:2025-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持:重庆聚合科技有限公司 地址:北京市东城区东交民巷1号(100730)